FREE

MOSL: EXPERT SPEAK-Healthcare – Domestic pharma market growth slowing down

EXPERT SPEAK: Healthcare – Domestic pharma market growth slowing down; Volume growth/share of generic-generic remains the key

 

Mr. Ameesh Masurekar; Director at AIOCD

Mr. Ameesh Masurekar is a Director at AIOCD, an organization that provides accurate data in a timely manner, helping the end-user make a fast and astute decision.

He has widespread experience in pharmaceutical sales and marketing, particularly in branded generics for the Indian market. He possesses deep insight in the Indian pharmaceutical distribution and retail sector and is well acquainted with the ground level work.

Mr. Masurekar is an MBA from Mumbai University and has previously worked with Eli Lilly, Nicholas Piramal and Panacea Biotech. 

We met Mr. Ameesh Masurekar, Director of AIOCD. Key takeaways from the meeting are:

• Industry volume growth might remain tepid, resulting in an approximate 11% industry growth over the next 4-5 years.
• Share of generic-generic is on the rise and is further impacting growth prospects of the branded formulation segment in the Indian Pharmaceutical market (IPM).
• With the recent ban on fixed dose combinations (FDC), in-licensing can provide good opportunities, in addition to in-house product development.
• On MAT basis, Lupin has been the best performer among Indian companies and Abbott India among MNCs.

View on the overall industry growth rate and key factors impacting the same:

• Among the key growth drivers of the Indian pharmaceutical industry. (volume/price/new launches), price growth is in the range of 4-5% while new launch growth is 2-3%. The balance growth is volume-driven; hence, it’s a key parameter to determine long-term industry growth.
• Volume growth is largely led by anti-infective (which constitute 14% of domestic sales) therapeutic segment, which is the largest category in value terms. With acute diseases gradually reducing on increased hygiene factors and lower epidemics, growth of this segment is moderating, which might impact overall industry volume growth.
• In addition, many co-prescription and co-therapies that are dependent on anti-infective, like vitamins, pain & analgesics and antacids could further suppress the overall volume growth.